William D. Shipman, MD, PhD

• Jeffrey Cohen
• Jonathan Leventhal
• Mary Tomayko
• William Damsky

Dermatology; Wound Healing; Stromal Cells; Hidradenitis Suppurativa; Exosomes; Extracellular Vesicles; Diversity, Equity, Inclusion

• Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatmentShipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.
• A protective Langerhans cell–keratinocyte axis that is dysfunctional in photosensitivityShipman WD, Chyou S, Ramanathan A, Izmirly PM, Sharma S, Pannellini T, Dasoveanu DC, Qing X, Magro CM, Granstein RD, Lowes MA, Pamer EG, Kaplan DH, Salmon JE, Mehrara BJ, Young JW, Clancy RM, Blobel CP, Lu TT. A protective Langerhans cell–keratinocyte axis that is dysfunctional in photosensitivity. Science Translational Medicine 2018, 10 PMID: 30111646, PMCID: PMC6365282, DOI: 10.1126/scitranslmed.aap9527.
• Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in MacrophagesCarmona-Rivera C, O'Neil LJ, Patino-Martinez E, Shipman WD, Zhu C, Li QZ, Kerns ML, Barnes LA, Caffrey JA, Kang S, Kaplan MJ, Okoye GA, Byrd AS. Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages. Journal Of Investigative Dermatology 2021, 142: 924-935. PMID: 34606886, PMCID: PMC8860851, DOI: 10.1016/j.jid.2021.07.187.
• Specimen Collection for Translational Studies in Hidradenitis SuppurativaByrd AS, Dina Y, Okoh UJ, Quartey QQ, Carmona-Rivera C, Williams DW, Kerns ML, Miller RJ, Petukhova L, Naik HB, Barnes LA, Shipman WD, Caffrey JA, Sacks JM, Milner SM, Aliu O, Broderick KP, Kim D, Liu H, Dillen CA, Ahn R, Frew JW, Kaplan MJ, Kang S, Garza LA, Miller LS, Alavi A, Lowes MA, Okoye GA. Specimen Collection for Translational Studies in Hidradenitis Suppurativa. Scientific Reports 2019, 9: 12207. PMID: 31434914, PMCID: PMC6704132, DOI: 10.1038/s41598-019-48226-w.
• An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic reviewShipman WD, Vernice NA, Demetres M, Jorizzo JL. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. Journal Of The American Academy Of Dermatology 2019, 82: 709-722. PMID: 31306730, DOI: 10.1016/j.jaad.2019.07.027.
• Fibroblast subtypes in tissues affected by autoimmunity: with lessons from lymph node fibroblastsShipman WD, Sandoval MJ, Veiga K, Donlin LT, Lu TT. Fibroblast subtypes in tissues affected by autoimmunity: with lessons from lymph node fibroblasts. Current Opinion In Immunology 2020, 64: 63-70. PMID: 32387902, PMCID: PMC7963142, DOI: 10.1016/j.coi.2020.03.002.
• Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativaSeltzer JA, Okeke CAV, Perry JD, Shipman WD, Okoye GA, Byrd AS. Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa. Journal Of The American Academy Of Dermatology 2020, 83: e153-e154. PMID: 32389715, PMCID: PMC7205672, DOI: 10.1016/j.jaad.2020.05.012.
• Tertiary lymphoid organs in systemic autoimmune diseases: pathogenic or protective?Shipman WD, Dasoveanu DC, Lu TT. Tertiary lymphoid organs in systemic autoimmune diseases: pathogenic or protective? F1000Research 2017, 6: 196. PMID: 28344775, PMCID: PMC5333609, DOI: 10.12688/f1000research.10595.1.
• Hidradenitis suppurativa in Black and White patients - a clinical study.Byrd A, Rosenberg A, Shipman W, Okoh U, Mazhar M, Okoye G, Bragazzi N, Mortellaro C, Jemec G, Damiani G. Hidradenitis suppurativa in Black and White patients - a clinical study. European Review For Medical And Pharmacological Sciences 2023, 27: 92-98. PMID: 37129339, DOI: 10.26355/eurrev_202304_31325.
• Treating hidradenitis suppurativa during the COVID-19 pandemic: teledermatology exams of sensitive body areasOkeke CAV, Shipman WD, Perry JD, Kerns ML, Okoye GA, Byrd AS. Treating hidradenitis suppurativa during the COVID-19 pandemic: teledermatology exams of sensitive body areas. Journal Of Dermatological Treatment 2020, 33: 1163-1164. PMID: 32643464, DOI: 10.1080/09546634.2020.1781042.
• Clinical Trials and Skin of Color: The Example of Hidradenitis SuppurativaOkeke CAV, Perry JD, Simmonds FC, Erskine AB, Shipman WD, Seltzer JA, Andrews MR, Saini AD, Cole TA, Perkins JA, Otado J, Kwagyan J, Collins CIF, Okoye GA, Byrd AS. Clinical Trials and Skin of Color: The Example of Hidradenitis Suppurativa. Dermatology 2021, 238: 180-184. PMID: 34107480, DOI: 10.1159/000516467.
• Lessons learned from the development of a hidradenitis suppurativa xenograft mouse modelQuartey QQ, Miller RJ, Pinsker BL, Okoh UJ, Shipman WD, George BA, Nwizu CC, Barnes LA, Kerns ML, Caffrey JA, Aliu O, Brown ID, Succaria F, Maynard JP, Herbert AS, Kang S, Miller LS, Okoye GA, Byrd AS. Lessons learned from the development of a hidradenitis suppurativa xenograft mouse model. Clinical And Experimental Dermatology 2019, 45: 202-206. PMID: 31322280, DOI: 10.1111/ced.14054.
• Lymph node stromal CCL2 limits antibody responsesDasoveanu DC, Park HJ, Ly CL, Shipman WD, Chyou S, Kumar V, Tarlinton D, Ludewig B, Mehrara BJ, Lu TT. Lymph node stromal CCL2 limits antibody responses. Science Immunology 2020, 5 PMID: 32198221, PMCID: PMC7490901, DOI: 10.1126/sciimmunol.aaw0693.
• Lymphatic Function in Autoimmune DiseasesSchwartz N, Chalasani MLS, Li TM, Feng Z, Shipman WD, Lu TT. Lymphatic Function in Autoimmune Diseases. Frontiers In Immunology 2019, 10: 519. PMID: 30949174, PMCID: PMC6435962, DOI: 10.3389/fimmu.2019.00519.
• Regulation of Lymph Node Vascular–Stromal Compartment by Dendritic CellsDasoveanu DC, Shipman WD, Chia JJ, Chyou S, Lu TT. Regulation of Lymph Node Vascular–Stromal Compartment by Dendritic Cells. Trends In Immunology 2016, 37: 764-777. PMID: 27638128, PMCID: PMC5492966, DOI: 10.1016/j.it.2016.08.013.
• Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody-Positive Patients with Livedo.Sevim E, Siddique S, Chalasani MLS, Chyou S, Shipman W, O'Shea O, Harp J, Alpan O, Zuily S, Lu T, Erkan D. Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody-Positive Patients with Livedo. The Journal Of Rheumatology 2022, 49: 1026-1030. PMID: 35649551, DOI: 10.3899/jrheum.220049.